• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表达[具体病毒名称]致密颗粒蛋白5的病毒样颗粒诱导的保护效力 。 你提供的原文不完整,缺少具体病毒名称等关键信息,我按照格式要求先进行了翻译,你可补充完整内容后继续向我提问。

Protective Efficacy Induced by Virus-like Particles Expressing Dense Granule Protein 5 of .

作者信息

Heo Su In, Kang Hae-Ji, Mao Jie, Yang Zhao-Shou, Ahmed Md Atique, Quan Fu-Shi

机构信息

Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.

Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, Core Research Institute (CRI), Kyung Hee University, Seoul 02447, Republic of Korea.

出版信息

Vaccines (Basel). 2025 Jul 24;13(8):787. doi: 10.3390/vaccines13080787.

DOI:10.3390/vaccines13080787
PMID:40872874
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12390477/
Abstract

() causes severe disease in immunocompromised individuals and pregnant women, underscoring the urgent need for effective vaccines against toxoplasmosis. The dense granule protein 5 (GRA5) of plays a key role in parasitic cyst formation. This study evaluated the protective immune responses induced by a virus-like particle (VLP) vaccine expressing the -derived antigen GRA5 in a mouse model challenged with the ME49 strain of . GRA5 VLPs were generated using a baculovirus expression system, and VLP formation was confirmed by Western blotting and visualized using transmission electron microscopy. Mice were intranasally immunized with GRA5 VLPs three times at 4-week intervals to induce immune responses, followed by infection with ME49. Intranasal immunization with GRA5 VLPs induced parasite-specific IgG antibody responses in the serum and both IgG and IgA antibody responses in the brain. Compared to the non-immunized group, immunized mice exhibited significantly higher levels of germinal center B cells and antibody-secreting cell responses. Moreover, the VLP vaccine suppressed the production of IFN-γ and IL-6 cytokines, leading to a significant reduction in brain inflammation and decreased cyst counts following lethal challenge with ME49 infection. These findings suggest that the GRA5 VLP vaccine derived from elicits a protective immune response, highlighting its potential as an effective vaccine candidate against toxoplasmosis.

摘要

()在免疫功能低下的个体和孕妇中会引发严重疾病,这凸显了迫切需要有效的抗弓形虫疫苗。弓形虫的致密颗粒蛋白5(GRA5)在寄生虫囊肿形成中起关键作用。本研究在受到弓形虫ME49株攻击的小鼠模型中,评估了表达弓形虫来源抗原GRA5的病毒样颗粒(VLP)疫苗诱导的保护性免疫反应。使用杆状病毒表达系统产生GRA5 VLP,并通过蛋白质免疫印迹法确认VLP的形成,并用透射电子显微镜观察其形态。小鼠每隔4周鼻内免疫三次GRA5 VLP以诱导免疫反应,随后感染弓形虫ME49株。鼻内免疫GRA5 VLP可在血清中诱导寄生虫特异性IgG抗体反应,并在脑中诱导IgG和IgA抗体反应。与未免疫组相比,免疫小鼠的生发中心B细胞水平和抗体分泌细胞反应显著更高。此外,VLP疫苗抑制了IFN-γ和IL-6细胞因子的产生,导致在受到弓形虫ME49感染致死攻击后脑部炎症显著减轻,囊肿数量减少。这些发现表明,源自弓形虫的GRA5 VLP疫苗可引发保护性免疫反应,突出了其作为抗弓形虫有效候选疫苗的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c09c/12390477/9d2971fbede7/vaccines-13-00787-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c09c/12390477/d005adaa133b/vaccines-13-00787-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c09c/12390477/4dc8171283f1/vaccines-13-00787-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c09c/12390477/016d70404faa/vaccines-13-00787-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c09c/12390477/ead87e6e363b/vaccines-13-00787-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c09c/12390477/bcea20d7173c/vaccines-13-00787-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c09c/12390477/9d2971fbede7/vaccines-13-00787-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c09c/12390477/d005adaa133b/vaccines-13-00787-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c09c/12390477/4dc8171283f1/vaccines-13-00787-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c09c/12390477/016d70404faa/vaccines-13-00787-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c09c/12390477/ead87e6e363b/vaccines-13-00787-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c09c/12390477/bcea20d7173c/vaccines-13-00787-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c09c/12390477/9d2971fbede7/vaccines-13-00787-g006.jpg

相似文献

1
Protective Efficacy Induced by Virus-like Particles Expressing Dense Granule Protein 5 of .表达[具体病毒名称]致密颗粒蛋白5的病毒样颗粒诱导的保护效力 。 你提供的原文不完整,缺少具体病毒名称等关键信息,我按照格式要求先进行了翻译,你可补充完整内容后继续向我提问。
Vaccines (Basel). 2025 Jul 24;13(8):787. doi: 10.3390/vaccines13080787.
2
Influenza virus-like particles presenting dense granule protein 7 protect mice from lethal ME49 challenge.呈现致密颗粒蛋白7的流感病毒样颗粒可保护小鼠免受致死性ME49攻击。
Nanomedicine (Lond). 2025 Sep;20(18):2309-2320. doi: 10.1080/17435889.2025.2546769. Epub 2025 Aug 13.
3
Virus-like particle vaccine displaying Toxoplasma gondii apical membrane antigen 1 induces protection against T. gondii ME49 infection in mice.展示刚地弓形虫顶膜抗原1的病毒样颗粒疫苗可诱导小鼠抵抗刚地弓形虫ME49感染。
Microb Pathog. 2020 Feb 22;142:104090. doi: 10.1016/j.micpath.2020.104090.
4
A novel combined quadrivalent self-amplifying mRNA-LNP vaccine provokes protective immunity against acute and chronic toxoplasmosis in mice.一种新型组合四价自扩增mRNA-LNP疫苗可激发小鼠对急性和慢性弓形虫病的保护性免疫。
Infect Dis Poverty. 2025 Jun 23;14(1):55. doi: 10.1186/s40249-025-01332-6.
5
Protective efficacy of recombinant Toxoplasma gondii dense granule protein 15 against toxoplasmosis in C57BL/6 mice.重组弓形虫致密颗粒蛋白 15 对 C57BL/6 小鼠弓形虫病的保护作用。
Vaccine. 2024 Apr 2;42(9):2299-2309. doi: 10.1016/j.vaccine.2024.02.062. Epub 2024 Feb 29.
6
Efficacy of Heterologous Vaccination Using Virus-Like Particles and Vaccinia Virus Containing MIC8 and AMA1 Proteins of .使用包含疟原虫MIC8和AMA1蛋白的病毒样颗粒和痘苗病毒进行异源疫苗接种的效果 。 (原文句末不完整,推测可能是“疟原虫”等相关内容)
Vaccines (Basel). 2025 Aug 15;13(8):862. doi: 10.3390/vaccines13080862.
7
[Generation of a dense granule protein 3 gene-deficient strain of and its virulence testing].[猪痢疾短螺旋体致密颗粒蛋白3基因缺陷株的构建及其毒力检测]
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2025 Jun 4;37(3):304-309. doi: 10.16250/j.32.1915.2024293.
8
Protective effect against toxoplasmosis in BALB/C mice vaccinated with recombinant Toxoplasma gondii CDPK3, GRA35, and ROP46 protein cocktail vaccine.用重组弓形虫 CDPK3、GRA35 和 ROP46 蛋白鸡尾酒疫苗免疫 BALB/C 小鼠对弓形虫病的保护作用。
Vaccine. 2024 Feb 27;42(6):1342-1351. doi: 10.1016/j.vaccine.2024.01.050. Epub 2024 Feb 2.
9
Immunogenicity and Protective Efficacy of a Recombinant GRA12 Vaccine in Domestic Cats.重组GRA12疫苗在家猫中的免疫原性和保护效力
Vaccines (Basel). 2025 Aug 11;13(8):851. doi: 10.3390/vaccines13080851.
10
Recombinant vaccinia virus expressing MIC8, AMA1, or RON4 induce protection against Toxoplasma gondii ME49 strain infection.表达MIC8、AMA1或RON4的重组痘苗病毒可诱导对刚地弓形虫ME49株感染的保护作用。
Acta Trop. 2025 Aug 29;270:107812. doi: 10.1016/j.actatropica.2025.107812.

本文引用的文献

1
Protective humoral immunity induced by virus-like particles expressing Toxoplasma gondii CST1 or MIC8.表达刚地弓形虫CST1或MIC8的病毒样颗粒诱导的保护性体液免疫
Acta Trop. 2025 Jan;261:107501. doi: 10.1016/j.actatropica.2024.107501. Epub 2024 Dec 16.
2
Heterologous immunization targeting the CST1 antigen confers better protection than ROP18 in mice.针对 CST1 抗原的异源免疫比 ROP18 更能在小鼠中提供更好的保护。
Nanomedicine (Lond). 2024;19(29):2437-2446. doi: 10.1080/17435889.2024.2403333. Epub 2024 Sep 25.
3
Virus-like particles expressing microneme-associated antigen of Plasmodium berghei confer better protection than those expressing apical membrane antigen 1.
表达伯氏疟原虫微线体相关抗原的病毒样颗粒比表达顶膜抗原 1 的病毒样颗粒具有更好的保护效果。
Parasites Hosts Dis. 2024 May;62(2):193-204. doi: 10.3347/PHD.24017. Epub 2024 May 27.
4
Exploring the potential of Toxoplasma gondii in drug development and as a delivery system.探索刚地弓形虫在药物开发和作为输送系统中的潜力。
Exp Mol Med. 2024 Feb;56(2):289-300. doi: 10.1038/s12276-024-01165-7. Epub 2024 Feb 1.
5
The detection of Toxoplasma gondii ME49 infections in BALB/c mice using various techniques.使用不同技术检测 BALB/c 小鼠中的刚地弓形虫 ME49 感染。
Parasites Hosts Dis. 2023 Nov;61(4):418-427. doi: 10.3347/PHD.23048. Epub 2023 Nov 28.
6
Protective mucosal and systemic immunity induced by virus-like particles expressing Toxoplasma gondii cyst wall protein.表达刚地弓形虫囊壁蛋白的病毒样颗粒诱导的保护性黏膜和系统免疫。
PLoS One. 2023 Apr 27;18(4):e0283928. doi: 10.1371/journal.pone.0283928. eCollection 2023.
7
Orally Administrated Recombinant Vaccinia Virus Displaying ROP4 Induces Protection against Challenge Infection.口服表达ROP4的重组痘苗病毒可诱导对攻毒感染的保护作用。
Vaccines (Basel). 2022 Jan 20;10(2):152. doi: 10.3390/vaccines10020152.
8
Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains.表达严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突糖蛋白、S1或S2结构域的流感病毒样颗粒(VLP)疫苗
Vaccines (Basel). 2021 Aug 18;9(8):920. doi: 10.3390/vaccines9080920.
9
Advances in Vaccines: Current Strategies and Challenges for Vaccine Development.疫苗进展:疫苗研发的当前策略与挑战
Vaccines (Basel). 2021 Apr 21;9(5):413. doi: 10.3390/vaccines9050413.
10
Toxoplasma gondii virus-like particle vaccination alleviates inflammatory response in the brain upon T gondii infection.刚地弓形虫病毒样颗粒疫苗接种可减轻弓形虫感染时大脑的炎症反应。
Parasite Immunol. 2020 Jun;42(6):e12716. doi: 10.1111/pim.12716. Epub 2020 Apr 20.